We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

48 hedge funds and large institutions have $156M invested in Protara Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 1

45% more funds holding

Funds holding: 33 → 48 (+15)

36% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 11

33% more capital invested

Capital invested by funds: $118M → $156M (+$38.6M)

21.26% more ownership

Funds ownership: 67.81% → 89.06% (+21%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
48
Holders Change
+15
Holders Change %
+45.45%
% of All Funds
0.97%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
16
Increased
15
Reduced
11
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
+$14.9M
2
PA
Perceptive Advisors
New York
+$14.1M
3
CAM
Cormorant Asset Management
Massachusetts
+$10.4M
4
O
OrbiMed
New York
+$10.4M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.4M

Top Sellers

Rank Fund Capital Flow
1
A
Abingworth
United Kingdom
-$765K
2
EP
Eversept Partners
New York
-$232K
3
HF
HRT Financial
New York
-$215K
4
Bank of America
Bank of America
North Carolina
-$40.8K
5
UBS Group
UBS Group
Switzerland
-$12.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$43.1M +$8.12M +350,000 +16%
DM
2
Deerfield Management
New York
$13.2M +$8.12M +350,000 +81%
IC
3
Ikarian Capital
Texas
$12.2M +$4.51M +194,479 +37%
RSCM
4
Rock Springs Capital Management
Maryland
$10.8M +$14.9M +643,622 New
PA
5
Perceptive Advisors
New York
$10.2M +$14.1M +608,544 New
CAM
6
Cormorant Asset Management
Massachusetts
$7.57M +$10.4M +450,000 New
O
7
OrbiMed
New York
$7.57M +$10.4M +450,000 New
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$7.54M +$10.4M +448,093 New
FCM
9
Farallon Capital Management
California
$7.15M +$9.86M +425,000 New
Franklin Resources
10
Franklin Resources
California
$5.89M +$8.12M +350,000 New
Artisan Partners
11
Artisan Partners
Wisconsin
$4.99M +$6.87M +296,384 New
BC
12
Boxer Capital
California
$3.52M – – –
Alyeska Investment Group
13
Alyeska Investment Group
Illinois
$3.37M +$4.64M +200,000 New
BBA
14
Baker Bros. Advisors
New York
$3.36M – – –
CH
15
CVI Holdings
Delaware
$2.84M +$3.92M +168,836 New
CAC
16
Cowen and Company
New York
$2.09M +$2.88M +124,171 New
MS
17
Maven Securities
Jersey
$1.69M +$2.32M +100,000 New
SCM
18
Soleus Capital Management
Connecticut
$1.68M +$2.32M +100,000 New
BlackRock
19
BlackRock
New York
$1.55M -$3.52K -152 -0.2%
BFM
20
Boothbay Fund Management
New York
$1.09M +$479K +20,659 +47%
Renaissance Technologies
21
Renaissance Technologies
New York
$636K +$181K +7,800 +26%
Northern Trust
22
Northern Trust
Illinois
$621K +$472K +20,371 +123%
EP
23
Eversept Partners
New York
$611K -$232K -10,000 -22%
TD Asset Management
24
TD Asset Management
Ontario, Canada
$424K +$584K +25,185 New
State Street
25
State Street
Massachusetts
$387K +$113K +4,861 +27%
1
2

TARA Hedge Fund Activity: Q3 2020 in Review

48 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2020, worth a combined $156M — up 33% from $118M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new TARA positions and 1 closed out — a net gain of 15 holders — while 15 added to existing stakes and 11 trimmed.

The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $14.9M. The largest seller was Abingworth, cutting an estimated $765K.

  • 48 institutional investors held Protara Therapeutics (TARA) as of Q3 2020, up from 33 in Q2 2020.
  • Funds reported $156M of Protara Therapeutics stock for Q3 2020, up 33% quarter-over-quarter.
  • 16 funds opened new Protara Therapeutics positions in Q3 2020 and 1 closed out, a net change of +15 holders.
  • The largest Protara Therapeutics buyer in Q3 2020 was Rock Springs Capital Management, an estimated $14.9M added.
  • The largest Protara Therapeutics seller in Q3 2020 was Abingworth, an estimated $765K sold.

Based on aggregated 13F filings for Q3 2020.